Klassen D, Goodfriend T L, Schuna A A, Young D Y, Peterson C A
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201-1595.
J Clin Pharmacol. 1993 Oct;33(10):971-8. doi: 10.1002/j.1552-4604.1993.tb01932.x.
This study determined the effect of nonsteroidal anti-inflammatory drug (NSAID) administration on blood pressure in hypertensive patients taking hydrochlorothiazide (HCTZ). Ninety-seven patients with mild essential hypertension and a musculoskeletal indication for NSAID use were studied in a three-phase, multi-center, double-blind, randomized, parallel study based in 15 academic and community clinics. Patients served as their own controls. Patients with stable hypertension, not taking antihypertensive or NSAID medications, were treated with HCTZ 50 mg/day. After 4 to 5 weeks of treatment and documented stable blood pressure, naproxen 375 mg twice a day or ibuprofen 800 mg three times a day was added. Blood pressure was measured at 2 and 4 weeks of NSAID therapy. The average diastolic blood pressure was 97.5 +/- 2.4 mm Hg and the average of the mean arterial pressure (MAP) was 116.8 +/- 6.04 before treatment with HCTZ. Hydrochlorothiazide treatment decreased diastolic blood pressure to 83.1 +/- 5.6 mm Hg, and MAP to 101.1 +/- 6.5 mm Hg. With naproxen or ibuprofen treatments, mean diastolic blood pressure increased less than 3 mm Hg. At 2 weeks, ibuprofen increased diastolic blood pressure by 2.6 mm Hg (P = .004) and naproxen increased diastolic blood pressure 0.7 mm Hg (P = .40). Both ibuprofen and naproxen significantly increased diastolic pressure at 4 weeks (2.1 mm Hg, P = .042; and 1.8 mm Hg, P = .043, respectively). There was no correlation between the pre-NSAID blood pressure and the magnitude of change after 2 or 4 weeks of treatment. Changes in MAP reflected a pattern similar to diastolic pressure.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究确定了服用氢氯噻嗪(HCTZ)的高血压患者使用非甾体抗炎药(NSAID)对血压的影响。在15家学术和社区诊所开展的一项三阶段、多中心、双盲、随机、平行研究中,对97例患有轻度原发性高血压且有NSAID使用的肌肉骨骼适应症的患者进行了研究。患者自身作为对照。血压稳定、未服用抗高血压或NSAID药物的患者接受50毫克/天的氢氯噻嗪治疗。治疗4至5周且血压记录稳定后,添加萘普生375毫克,每日两次,或布洛芬800毫克,每日三次。在NSAID治疗的第2周和第4周测量血压。在使用氢氯噻嗪治疗前,平均舒张压为97.5±2.4毫米汞柱,平均动脉压(MAP)为116.8±6.04。氢氯噻嗪治疗使舒张压降至83.1±5.6毫米汞柱,MAP降至101.1±6.5毫米汞柱。使用萘普生或布洛芬治疗时,平均舒张压升高不到3毫米汞柱。在第2周,布洛芬使舒张压升高2.6毫米汞柱(P = .004),萘普生使舒张压升高0.7毫米汞柱(P = .40)。在第4周,布洛芬和萘普生均使舒张压显著升高(分别为2.1毫米汞柱,P = .042;和1.8毫米汞柱,P = .043)。NSAID治疗前的血压与治疗2周或4周后的变化幅度之间无相关性。MAP的变化反映出与舒张压相似的模式。(摘要截断于250字)